key: cord-0707589-495qavc5 authors: Khan, Tahsin Shahrin; Shirin, Dr. Tahmina; Alam, Dr. Ahmed Nawsher; Shakhider, Mohammad Abdul Hannan; Haque, Fahim title: Follow-up of Practiced Treatment Regimens & Health Conditions of Recovered Patients of COVID-19 Residing in Dhaka City: A Survey-based Descriptive Cross-sectional Study date: 2022-03-14 journal: IJID Regions DOI: 10.1016/j.ijregi.2022.03.005 sha: 245c738801e1a63cb67b0d5470c2c4ba80b8e977 doc_id: 707589 cord_uid: 495qavc5 Objective This survey-based cross-sectional descriptive study aimed to observe the prognosis of COVID-19 cases, focusing on the symptoms, treatment, and post-recovery health conditions. Methodology The respondents were Dhaka city (Bangladesh) residents, with a RT-PCR confirmed diagnosis of coronavirus-19 from the Institute of Epidemiology, Disease Control and Research (IEDCR) from October to December 2020. They were followed up 1 to 3 months after diagnosis, data were collected via Google forms directly sent through emails and were analyzed using SPSS. Participation was consensual, and confidentiality of the respondents was strictly maintained. Results Out of 3,148 recovered patients, 522 patients responded to the survey. The mean age and BMI of the respondents was 39.8±13 years and 26.4±6.5 kg/m2 respectively. Males (70.3%) were found more affected. Around 39.3% had various comorbidities. About 88.5% of the respondents suffered from various symptoms, including fever, fatigue, anosmia and aguesia, body pain, headache, dry cough, etc. for minimum 1 to 5 days. The respondents were treated with antibiotics (72.4%), antiparasitic (47.9%), antivirals (15.9%) etc. A mean of 19.7±7.6 days was required for respondents to become RT-PCR negative. Various symptoms like fatigue, anxiety, depression, uneasiness, body pain, dry cough, etc., persisted in 76.3% of the respondents. Conclusion For most, becoming symptom-free took longer than RT-PCR negativity. Similar study should be conducted to see the changing status of COVID-19. Health Organization, 2020). Additionally, some clinical trials showed that Favipiravir, a nextgeneration antiviral drug accelerates the viral clearance and improve the lung conditions of patients; Ivermectin, a broad-spectrum antiparasitic drug showed efficacious results when combined with Hydroxychloroquine, Ribavirin, a guanosine analogue, and Corticosteroids The objective of this study was to help understand the prognosis of COVID-19 in Dhaka during the months of October to December 2020. The study focused on the symptoms, treatment, and post-recovery health conditions. It was expected that this study would provide a needed overview of the practiced treatment regimens of the covid patients of Dhaka city. Descriptive Cross-sectional study. For this survey, the sample size was calculated to be around 384 based on 50% prevalence rate (p), 5% error (d), and 95% Confidence Interval (z). This study followed 522 patients in Dhaka, Bangladesh, during January and February 2021, diagnosed with SARS-CoV-2 infection between October to December 2020, at the Institute of Epidemiology, Disease Control and Research (IEDCR) to assess the symptoms, treatment regimens and post-COVID-19 sequelae. The study population was selected using three inclusion criteria: (i) all patients diagnosed with Among the 522 respondents, 39.3% (n=205) patients had various pre-existing comorbidities. Major comorbidities among them were, Hypertension (56.6%), Diabetes (38.1%), Asthma (26.3%), Cardiac diseases (12.2%) (Fig. 1) . Moreover, respondents with pre-existing health conditions mostly developed various symptoms of COVID-19 (Table-3) . While being infected with SARS-CoV-2, 88.5% (n=462) respondents experienced multiple symptoms while 11.5% were asymptomatic (Table-1 ). (Table-S1 ). The respondents reported that most symptoms (i.e., fever, cough, headache, shortness of breath, nasal congestion or runny nose, nausea or vomiting, body pain, chest pain) lasted for 1 to 5 days from the onset of the disease, whereas 33.3% of the respondents felt fatigue for more than 20 days (Table-S2 ). Among the 522 respondents, 80.08% repeated the RT-PCR-test after a significant period of time from their first diagnosis (Figure-S2 ). The mean days to RT-PCR negativity for COVID-19 was 19.7±7.6 days. Around 23.8% of the respondents suffered with no persisting symptoms after tested negative; however, others suffered from one-to-many persisting symptoms (Table-S3 Among the asymptomatic respondents, 65% (n=39) developed various symptoms after being tested negative for COVID-19. Whereas 77.7% (n=359) symptomatic respondents experienced various symptoms even after recovery. A significant association exists between past and persisting symptoms of the respondents, which is significant at the level of 3% (Table-6 ). Pearson's correlation coefficient showed a weak positive correlation between age and days to negative RT-PCR results, r (416) =0.135, p = 0.006; i.e., with the increase in age, the days to negative RT-PCR result for COVID-19 also increase. There was a weak positive correlation between the number of comorbidities and days to negative RT-PCR result, r (416) =0.144, p = 0.003. It indicates that with the increase of the number of comorbidities in respondents, days to negative RT-PCR result for the infection will also increase. There was a weak positive correlation between the number of symptoms during illness with days to negative RT-PCR result, r (416) =0.140, p = 0.004. i.e., with the increase of the number of symptoms, days to negative RT-PCR result for the infection will also increase ( Table-7) . The association of days to negative RT-PCR results and medications taken by the respondents were tested by independent t-test. Except for antibiotic therapy, the p-value is >0.05 for the other medications (Table-8) . Therefore, for these medications, the null hypothesis cannot be rejected at 5% level of significance. The tests (except for the test with antibiotic therapy) indicated that the average days to RT-PCR negativity of respondents who took these various medications and those who did not are not significantly different. This is a study on the clinical characteristics, and treatment of 522 (Table-S3 ). Even among the asymptomatic respondents, 65% developed various symptoms, after being tested negative. Amidst the symptomatic ones, 77.7% continued to suffer from various symptoms. Symptoms during illness were found significantly associated with persistent symptoms (Table-6 ). The study revealed that, with the increase of age, number of comorbidities, and symptoms during illness, the respondents required more days to obtain a negative RT-PCR result, which was statistically significant at the level of 1%. A significant association was also found between the use of antibiotics and days to negative RT-PCR results of the respondents. It seems from the results that the respondents who had undergone antibiotic treatment significantly took longer to recover than their counterparts. However, related studies couldn't be found to discuss these findings further in detail. The outcome of this study needs to be further verified by a larger sample with a multi-center study. Challenges relating to online surveys include chances of low response rate due to technological disadvantages, lower literacy levels, and lack of interest of the recipients to take part in the survey. Due to such challenges, all the patients who fell under our inclusion criteria were requested to take part in this survey through an email, and only those who self-reported within the two months of the survey were selected as a study subject for this study. We could not collect data on physical examinations (e.g., Respiratory rate, oxygen saturation, blood pressure, temperature, etc.) and laboratory findings (i.e., chest X-ray, CT-scans, D-dimer, etc.) due to time constraints. Thus, the disease severity of the respondents couldn't be assessed. Further study would provide more COVID-19 related information about Bangladesh. translated consent form can be found "here" for the better understanding of the readers. In case of the minors, the survey invitation and form were directly sent to their parent's email, collected from the Institute of Epidemiology, Disease Control and Research (IEDCR) database. During data collection and analysis, the privacy of the respondents and confidentiality of the data was maintained strictly. Participation in the survey was entirely voluntary, and the collected data was anonymously used only for this current study. Clinico-Pathological Findings of Bangladeshi Covid 19 Patients with their Clinical Outcome: Study of A Cohort Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis Persistent Symptoms in Patients After Acute COVID Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients Centers for Disease Control and Prevention COVID-2019) Bangladesh situation reports update/coronavirus-disease-(covid-2019)-bangladesh-situation-reports COVID-19) Centers for Disease Control and Prevention Clinical Characteristics of Coronavirus Disease 2019 in China Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus diseases (COVID-19) in Bangladesh: A Descriptive Study BMI as a Risk Factor for Clinical Outcomes in Patients Hospitalized with COVID-19 in New York Pathophysiology and treatment strategies for COVID-19 Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection Clinical Profile of 100 Confirmed COVID-19 Patients Admitted in Dhaka Medical College Hospital Update on treatment of COVID-19: ongoing studies between promising and disappointing results Solidarity" clinical trial for COVID-19 treatments Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis We are grateful for the stimulating discussions and comments by Dr. Mahboob Hossain, Dr.Mohammad Rafiqul Islam, Dr. Mahbubul Hasan Siddiqee, and Mr. Akash Ahmed. We also thank Dr. Razia Sultana, Dr. Iqbal Ansary Khan, and Ms. Rifat Shahpar Khan for being a great support throughout the study period, from development of the tools, study implementation to review and refinement. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. This study is independently funded by the authors. No external funding was required. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.